drugset
drugset / Trial / NCT01662505

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

NCT01662505 ↗

Phase 1 Completed 19 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML

Timeline

Start
2012-08
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Volasertib Small molecule — Intravenous

Indications

acute myeloid leukemia